Cargando…
Multistep, effective drug distribution within solid tumors
The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offe...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741846/ https://www.ncbi.nlm.nih.gov/pubmed/26416413 |
_version_ | 1782414083486646272 |
---|---|
author | Shemi, Amotz Khvalevsky, Elina Zorde Gabai, Rachel Malka Domb, Abraham Barenholz, Yechezkel |
author_facet | Shemi, Amotz Khvalevsky, Elina Zorde Gabai, Rachel Malka Domb, Abraham Barenholz, Yechezkel |
author_sort | Shemi, Amotz |
collection | PubMed |
description | The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offers an alternative to both systemic delivery and intratumoral injection. Presented here is a model of drug distribution from such a source, in a multistep process. At delivery onset the drug mainly affects the closest surroundings. Such ‘priming’ enables drug penetration to successive cell layers. Tumor ‘void volume’ (volume not occupied by cells) increases, facilitating lymphatic perfusion. The drug is then transported by hydraulic convection downstream along interstitial fluid pressure (IFP) gradients, away from the tumor core. After a week tumor cell death occurs throughout the entire tumor and IFP gradients are flattened. Then, the drug is transported mainly by ‘mixing’, powered by physiological bulk body movements. Steady state is achieved and the drug covers the entire tumor over several months. Supporting measurements are provided from the LODER™ system, releasing siRNA against mutated KRAS over months in pancreatic cancer in-vivo models. LODER™ was also successfully employed in a recent Phase 1/2 clinical trial with pancreatic cancer patients. |
format | Online Article Text |
id | pubmed-4741846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-47418462016-03-23 Multistep, effective drug distribution within solid tumors Shemi, Amotz Khvalevsky, Elina Zorde Gabai, Rachel Malka Domb, Abraham Barenholz, Yechezkel Oncotarget Research Paper The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offers an alternative to both systemic delivery and intratumoral injection. Presented here is a model of drug distribution from such a source, in a multistep process. At delivery onset the drug mainly affects the closest surroundings. Such ‘priming’ enables drug penetration to successive cell layers. Tumor ‘void volume’ (volume not occupied by cells) increases, facilitating lymphatic perfusion. The drug is then transported by hydraulic convection downstream along interstitial fluid pressure (IFP) gradients, away from the tumor core. After a week tumor cell death occurs throughout the entire tumor and IFP gradients are flattened. Then, the drug is transported mainly by ‘mixing’, powered by physiological bulk body movements. Steady state is achieved and the drug covers the entire tumor over several months. Supporting measurements are provided from the LODER™ system, releasing siRNA against mutated KRAS over months in pancreatic cancer in-vivo models. LODER™ was also successfully employed in a recent Phase 1/2 clinical trial with pancreatic cancer patients. Impact Journals LLC 2015-09-22 /pmc/articles/PMC4741846/ /pubmed/26416413 Text en Copyright: © 2015 Shemi et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Shemi, Amotz Khvalevsky, Elina Zorde Gabai, Rachel Malka Domb, Abraham Barenholz, Yechezkel Multistep, effective drug distribution within solid tumors |
title | Multistep, effective drug distribution within solid tumors |
title_full | Multistep, effective drug distribution within solid tumors |
title_fullStr | Multistep, effective drug distribution within solid tumors |
title_full_unstemmed | Multistep, effective drug distribution within solid tumors |
title_short | Multistep, effective drug distribution within solid tumors |
title_sort | multistep, effective drug distribution within solid tumors |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741846/ https://www.ncbi.nlm.nih.gov/pubmed/26416413 |
work_keys_str_mv | AT shemiamotz multistepeffectivedrugdistributionwithinsolidtumors AT khvalevskyelinazorde multistepeffectivedrugdistributionwithinsolidtumors AT gabairachelmalka multistepeffectivedrugdistributionwithinsolidtumors AT dombabraham multistepeffectivedrugdistributionwithinsolidtumors AT barenholzyechezkel multistepeffectivedrugdistributionwithinsolidtumors |